Pancreatic Cancer Research

ResearcherBinzhou Medical UniversityActive in the last 2 years

Maolei Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5318-1018; OpenAlex author ID A5059148106. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 4

  1. Neferine-Targeted Inhibition of TrxR1 Triggers Apoptosis Through Disrupting Redox Homeostasis in Pancreatic Cancer Cells. Co-author DOI 10.1002/mc.70157↗
  2. Tiliroside disrupted iron homeostasis and induced ferroptosis via directly targeting calpain-2 in pancreatic cancer cells. Co-author DOI 10.1016/j.phymed.2024.155392↗
  3. Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells. Last author DOI 10.1016/j.bcp.2021.114813↗
  4. YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine. Last author DOI 10.3390/biom9100620↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ling Zhou · 2 shared papers, 2021–2024 · strength 0.33
  2. Xiaoqing Yuan · 1 shared paper, 2026 · strength 0.27
  3. Ling Zhou · 1 shared paper, 2026 · strength 0.27
  4. Yufu Zhou · 1 shared paper, 2024 · strength 0.19
  5. Chen Yang · 1 shared paper, 2021 · strength 0.14
  6. Ling Zhou · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.